Implementation of the WHO integrated care for older people (ICOPE) programme in clinical practice: a prospective study

Tavassoli, Néda; Barreto, Philipe de Souto; Berbon, Caroline; Mathieu, Céline; Kerimel, J. de; Lafont, C.; Takeda, Catherine; Carrié, Isabelle; Piau, Antoine; Jouffrey, Tania; Andrieu, Sandrine; Nourhashémi, F.; Beard, John; Martín, María; Vellas, Bruno

doi:10.1016/s2666-7568(22)00097-6

Cited by 68 publications

(42 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In ICOPE step 1, memory is assessed by a subjective question, an orientation task, and a free recall of 3 words. In a population of about 18000 individuals with a mean age of 76 years old, it was shown that 60% presented either a subjective or an objective complaint ( 45 ). In 50 % of cases these alterations were persistent after 6 months (not published data).…”

Section: Blood Biomarkers In Clinical Practicementioning

confidence: 99%

Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force

Angioni¹,

Delrieu²,

Hansson

et al. 2022

J Prev Alz Dis

View full text Add to dashboard Cite

Timely and accurate diagnosis of Alzheimer’s disease (AD) in clinical practice remains challenging. PET and CSF biomarkers are the most widely used biomarkers to aid diagnosis in clinical research but present limitations for clinical practice (i.e., cost, accessibility). Emerging blood-based markers have the potential to be accurate, cost-effective, and easily accessible for widespread clinical use, and could facilitate timely diagnosis. The EU/US CTAD Task Force met in May 2022 in a virtual meeting to discuss pathways to implementation of blood-based markers in clinical practice. Specifically, the CTAD Task Force assessed: the state-of-art for blood-based markers, the current use of blood-based markers in clinical trials, the potential use of blood-based markers in clinical practice, the current challenges with blood-based markers, and the next steps needed for broader adoption in clinical practice.

show abstract

Section: Blood Biomarkers In Clinical Practicementioning

confidence: 99%

Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force

Angioni¹,

Delrieu²,

Hansson

et al. 2022

J Prev Alz Dis

View full text Add to dashboard Cite

show abstract

“…The Integrated Care for Older People (ICOPE) initiative proposed by the World Health Organization (WHO) might represent an opportunity in this direction as designed to reshape the care models toward a person-centered approach ( 27 , 28 ). For example, the Gérontopôle of Toulouse (France) has recently implemented clinical activities based on the ICOPE model ( 29 ). Persons included in the program may be asked to be part of research programs devoted to 1) the study of health trajectories and dynamics, and 2) the exploration of possible geroprotectors.…”

Section: Resilience In Frail Older Persons: Clinical and Biological A...mentioning

confidence: 99%

Resilience: Biological Basis and Clinical Significance - A Perspective Report from the International Conference on Frailty and Sarcopenia Research (ICFSR) Task Force

et al. 2022

View full text Add to dashboard Cite

The Resilience is a construct receiving growing attention from the scientific community in geriatrics and gerontology. Older adults show extremely heterogeneous (and often unpredictable) responses to stressors. Such heterogeneity can (at least partly) be explained by differences in resilience (i.e., the capacity of the organism to cope with stressors). The International Conference on Frailty and Sarcopenia Research (ICFSR) Task Force met in Boston (MA,USA) on April 20, 2022 to discuss the biological and clinical significance of resilience in older adults. The identification of persons with low resilience and the prompt intervention in this at-risk population may be critical to develop and implement preventive strategies against adverse events. Unfortunately, to date, it is still challenging to capture resilience, especially due to its dynamic nature encompassing biological, clinical, subjective, and socioeconomic factors. Opportunities to dynamically measure resilience were discussed during the ICFSR Task Force meeting, emphasizing potential biomarkers and areas of intervention. This article reports the results of the meeting and may serve to support future actions in the field.

show abstract

“…Intrinsic capacity can be considered an indirect measure of physical resilience through the physiologic reserve concept ( 31 ). The INSPIRE integrated care for older people (ICOPE)-CARE program conducted by the Gerontopole in Toulouse has recently introduced screening for intrinsic capacity using the ICOPE monitor and ICOPEBOT conversational robot with the aim of identifying high-risk older adults ( 32 ). Many countries are implementing programs such as frailty screening and multidomain interventions, incorporating nutrition and exercise at individual, community, and city levels to reverse, prevent, or delay the decline in physiological reserves, possibly improving resilience over the long term ( 33 – 38 ).…”

mentioning

confidence: 99%

Editorial: Resilience and the Future

et al. 2022

View full text Add to dashboard Cite

Implementation of the WHO integrated care for older people (ICOPE) programme in clinical practice: a prospective study

Cited by 68 publications

References 22 publications

Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force

Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force

Resilience: Biological Basis and Clinical Significance - A Perspective Report from the International Conference on Frailty and Sarcopenia Research (ICFSR) Task Force

Editorial: Resilience and the Future

Contact Info

Product

Resources

About